Mammalian target of rapamycin as a therapeutic target in osteoporosis

J Cell Physiol. 2018 May;233(5):3929-3944. doi: 10.1002/jcp.26161. Epub 2017 Sep 28.

Abstract

The mechanistic target of rapamycin (mTOR) plays a key role in sensing and integrating large amounts of environmental cues to regulate organismal growth, homeostasis, and many major cellular processes. Recently, mounting evidences highlight its roles in regulating bone homeostasis, which sheds light on the pathogenesis of osteoporosis. The activation/inhibition of mTOR signaling is reported to positively/negatively regulate bone marrow mesenchymal stem cells (BMSCs)/osteoblasts-mediated bone formation, adipogenic differentiation, osteocytes homeostasis, and osteoclasts-mediated bone resorption, which result in the changes of bone homeostasis, thereby resulting in or protect against osteoporosis. Given the likely importance of mTOR signaling in the pathogenesis of osteoporosis, here we discuss the detailed mechanisms in mTOR machinery and its association with osteoporosis therapy.

Keywords: homeostasis; mTOR signaling; osteoporosis bone; therapeutic target.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bone and Bones / metabolism
  • Humans
  • Osteoblasts / drug effects*
  • Osteoblasts / metabolism
  • Osteoclasts / drug effects*
  • Osteoclasts / metabolism
  • Osteoporosis / drug therapy*
  • Osteoporosis / pathology
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • TOR Serine-Threonine Kinases
  • Sirolimus